PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.84%
Revenue growth under 50% of AVGO's 6.32%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
1.17%
Gross profit growth under 50% of AVGO's 4.96%. Michael Burry would be concerned about a severe competitive disadvantage.
-4.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-4.84%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-4.33%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-2.63%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.66%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-1.22%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-66.26%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-110.46%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
461.77%
10Y revenue/share CAGR 1.25-1.5x AVGO's 416.86%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
113.91%
5Y revenue/share CAGR at 75-90% of AVGO's 134.28%. Bill Ackman would encourage strategies to match competitor’s pace.
36.69%
3Y revenue/share CAGR at 50-75% of AVGO's 62.33%. Martin Whitman would question if the firm lags behind competitor innovations.
428.36%
10Y OCF/share CAGR at 50-75% of AVGO's 580.47%. Martin Whitman might fear a structural deficiency in operational efficiency.
-76.31%
Negative 5Y OCF/share CAGR while AVGO is at 92.77%. Joel Greenblatt would question the firm’s operational model or cost structure.
-17.39%
Negative 3Y OCF/share CAGR while AVGO stands at 39.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
725.23%
Net income/share CAGR at 75-90% of AVGO's 869.72%. Bill Ackman would press for strategic moves to boost long-term earnings.
109.22%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
228.36%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1178.18%
10Y equity/share CAGR 1.25-1.5x AVGO's 862.23%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
153.95%
5Y equity/share CAGR is in line with AVGO's 165.61%. Walter Schloss would see parallel mid-term profitability and retention policies.
51.87%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.47%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
9.32%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.04%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
2.18%
Under 50% of AVGO's 5.15%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
3.96%
R&D dropping or stable vs. AVGO's 13.26%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
5.16%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.